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Hepatitis C virus (HCV) is well known etiological agent for
causing chronic hepatitis, liver cirrhosis and hepatocellular
carcinoma in developing as well as developed countries.
An estimated 170 million people are chronically infected
with HCV and 3–4 million people are newly infected
each year[1]. The World Health Organization estimates
that approximately 3% of the world population has been
infected with HCV.
HCV infections are serious public health concern in
Pakistan. The first description of HCV in Pakistan was
in 1992 and since then there is no proper review[2]. With
approximately 6% of the population being affected by it
(approximately 10 million)[3], it is becoming a Herculean
challenge. With the current disease burden, Pakistan has
left behind all the major developed countries like Japan,
USA and Europe[4].
The annual incidence of HCV in the industrialized nations
has fallen in recent years, primarily because of effective
blood screening efforts and increased education on the
dangers of needle sharing. Contrary to that the burden
of HCV related chronic liver disease (CLD) in Pakistan
has increased. Studies from the past showed that of all
patients presenting with CLD, 16.6% were anti-HCV
antibody positive but more recent data shows nearly
60–70% patients with CLD tend to be positive. Medical
literature had also reported that nearly 50% patients with
hepatocellular carcinoma (HCC) in Pakistan are anti- HCV
antibody positive.
Past medical literature reports a highly variable seroprevalence
of HCV from different studies in different population and
the trend continues within the same province. The reason is
primarily attributed to HCV being a blood-borne infection,
spreads rather sporadically or in micro epidemics. The

most predominant HCV genotype is genotype 3 (75-90%),
followed by genotypes 1, 2, and 5 [5].
In Pakistan, several population groups have been described
as being at increased risk of HCV infection. In several
published studies, the proportion of patients with HCV
infection who received injections is in the range of 16% to
100%. High prevalence of HCV has been recorded among
middle-aged (40-50 years) people[6]. Haemodialysis
patients were also noted to be at high risk of HCV infection.
High HCV prevalence (23.7% to 68.0%) has been noted in
this group of patients, and particularly those on long-term
haemodialysis[7].
There are about 1.5 million units of blood products
transfused each year in Pakistan[8]. Data on the safety of
this transfusion process is rare which may be due to the lack
of system of reporting infectious or non-infectious adverse
events. The risk of HCV transmission through blood
transfusion in Pakistan is still unknown but is considered to
be high due to a lack of appropriate screening of blood.
Also, number of studies have shown the relationship
between therapeutic injections using non-sterile needles
and the transmission of HCV [3]. There is an enormous
dependence on parenteral therapy for treatment, both in the
form of injections and infusion of drips, driven by cultural
beliefs in the power of parenteral therapy[6]. The general
population of Pakistan typically prefers to be treated
by injection rather than oral medication. Thus, patient
demands and financial incentives for doctors favor the use
of injectable treatment in patient care. Another significant
risk factor of HCV transmission which had previously been
reported from different regions of Pakistan is daily face and
armpit shaving at community barber shops. The delicate
skin of the face and armpit are susceptible to micro trauma,
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leading to possible exposure to HCV through a contaminated
traditional long-handled razor[3, 9]. Additional risk factors
that may be important modes of transmission include ear
piercing and non-sterile surgical and dental practices of
unqualified health care workers (quacks)[10].
The HCV epidemic in Pakistan continues to rise due to
lack of education and awareness of the disease, shortage
of medically qualified and scientifically trained health
care workers and lack of health infrastructure. The
government of Pakistan had taken some steps in this area
in the past, by announcing a national blood policy in 2003.
In 2001–2002 Pakistan received a grant from the Global
Alliance for Vaccines and Immunization (GAVI) that
has enabled the introduction of Hepatitis B vaccination
in routine Expanded Program on Immunization (EPI)
[11]. Vaccination for HBV as part of EPI was launched
in a nationwide vaccination campaign in 2004[12].
Unfortunately, HCV infection is not a notifiable disease
in Pakistan and there is no national data collection system
for evaluation of routine risk factors.
In March 2009, government officials reported the Senate
that around 8,800,000 people in Pakistan are suffering from
deadly hepatitis C while another 5,600,000 are affected by
hepatitis B[13] and that availability of diagnostic facilities
and awareness campaigns have un-earthed the hidden
burden of the disease. The Prime Minister Programme for
Prevention and Control of Hepatitis was launched in August
2005 with a total cost of Rs 2.594 billion for a period of five
years[12]. The number of patients with the disease since
then has increased significantly as the government started
to provide free treatment, though on a limited scale. When
the programme was launched in 2005-06 the number of
patients, most of them poor, who were registered and treated
at government hospitals were 10,815 and 1,000 for hepatitis
C and B respectively. For the year 2008-09 the figure is
84,773 and 7,204 respectively for the two categories of
the disease[13]. If we critically analyze the figures with
the present disease burden, we confront with the harsh fact
that the gap between people getting affected each year and
getting treatment is too wide and only a small population
is seeking care with yet uninvestigated numbers of actually
getting rid of the disease. The picture gets even gloomier if
we realize that this what government is reporting and the
ground reality may be even worse. The increasing HCV
epidemic is likely to progress to a considerable increase in
disease burden over the coming years.
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The pillars of HCV infection control are blood safety, the
prevention of needle sharing among Intravenous Drug
Users (IVD), the strict implementation of standardized
preventive measures in healthcare settings, screening of at
risk groups and treatment of chronic hepatitis with multiple
drug therapy (pegylated interferon and ribavirin). Despite
its public health importance, however, how surveillance
systems for hepatitis C should be designed is still a matter
of debate. Cross sectional surveys on at risk population
or groups are essential to estimate the burden of HCV
infection and to describe affected persons who will need
to be targeted for screening and treatment. However, they
reflect past transmission routes, provide no information on
the current dynamics of HCV transmission and no data on
people currently getting infected.
Although the world is now hearing about Hepatitis awareness
specially after commencement of the Hepatitis awareness
day On May 19th every year from 2008, numerous efforts
are required to prevent this day from becoming an event of
seminars, lectures and conferences and the rest of the year ,
we forget about the disease.
We are living unfortunately without HCV vaccine, because
of the virus high mutation rate and substantial heterogeneity
of the genome of HCV. Still it is largely treatable and HCV
infection can be cured by the existing antiviral drugs in
more than 50% of the patients[14]. So efforts should be
made to save the waste of at least 50% of these needless
lives. Hepatitis preventing measures should include a
situational analysis and a realistic assessment of the blood
requirement in the area, followed by recruitment and
maintenance of voluntary, non-remunerated blood donors
and standardization and regulation of appropriate blood
screening procedures. IDUs are numerous in Pakistani
society and though they have a disproportionately high
burden of health problems, they have been inadequately
studied. Disseminating adequate information about
all aspects of HCV is essential in developing patient
understanding of the disease. It appears such information
can only be effectively and reliably disseminated through
effective awareness strategies. We also propose that for
health promotion action, programmes should be made to
increase awareness and use of specially prepared video
clips for the prevention of disease. Media is one of the
instrumentalities which facilitates and gives a directional
thrust to the efforts to cure the disease if not to treat it. If
medicine can treat Hepatitis, media is capable to prevent
it with an ultimate goal to cure it through its capabilities
to impart education through entertainment.
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